Daniela Riganelli
University of Perugia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daniela Riganelli.
The EMBO Journal | 2001
Alexandre Reymond; Germana Meroni; Anna Fantozzi; Giuseppe Merla; Stefano Cairo; Lucilla Luzi; Daniela Riganelli; Elena Zanaria; Silvia Messali; Silvia Cainarca; Alessandro Guffanti; Saverio Minucci; Pier Giuseppe Pelicci; Andrea Ballabio
A functional genomic approach, based on systematic data gathering, was used to characterize a family of proteins containing a tripartite motif (TRIM). A total of 37 TRIM genes/proteins were studied, 21 of which were novel. The results demonstrate that TRIM proteins share a common function: by means of homo‐multimerization they identify specific cell compartments.
Journal of Clinical Investigation | 2003
Myriam Alcalay; Natalia Meani; Vania Gelmetti; Anna Fantozzi; Marta Fagioli; Annette Orleth; Daniela Riganelli; Carla Sebastiani; Enrico Cappelli; Cristina Casciari; Maria Teresa Sciurpi; Angela Rosa Mariano; Simone P. Minardi; Lucilla Luzi; Heiko Müller; Pier Paolo Di Fiore; Guido Frosina; Pier Giuseppe Pelicci
Acute myelogenous leukemias (AMLs) are genetically heterogeneous and characterized by chromosomal rearrangements that produce fusion proteins with aberrant transcriptional regulatory activities. Expression of AML fusion proteins in transgenic mice increases the risk of myeloid leukemias, suggesting that they induce a preleukemic state. The underlying molecular and biological mechanisms are, however, unknown. To address this issue, we performed a systematic analysis of fusion protein transcriptional targets. We expressed AML1/ETO, PML/RAR, and PLZF/RAR in U937 hemopoietic precursor cells and measured global gene expression using oligonucleotide chips. We identified 1,555 genes regulated concordantly by at least two fusion proteins that were further validated in patient samples and finally classified according to available functional information. Strikingly, we found that AML fusion proteins induce genes involved in the maintenance of the stem cell phenotype and repress DNA repair genes, mainly of the base excision repair pathway. Functional studies confirmed that ectopic expression of fusion proteins constitutively activates pathways leading to increased stem cell renewal (e.g., the Jagged1/Notch pathway) and provokes accumulation of DNA damage. We propose that expansion of the stem cell compartment and induction of a mutator phenotype are relevant features underlying the leukemic potential of AML-associated fusion proteins.
Oncogene | 2001
Myriam Alcalay; Annette Orleth; Carla Sebastiani; Natalia Meani; Ferdinando Chiaradonna; Cristina Casciari; Maria Teresa Sciurpi; Vania Gelmetti; Daniela Riganelli; Saverio Minucci; Marta Fagioli; Pier Giuseppe Pelicci
The pathogenesis of acute myeloid leukemia is associated with the appearance of oncogenic fusion proteins generated as a consequence of specific chromosome translocations. Of the two components of each fusion protein, one is generally a transcription factor, whereas the other partner is more variable in function, but often involved in the control of cell survival and apoptosis. As a consequence, AML-associated fusion proteins function as aberrant transcriptional regulators that interfere with the process of myeloid differentiation, determine a stage-specific arrest of maturation and enhance cell survival in a cell-type specific manner. The abnormal regulation of transcriptional networks occurs through common mechanisms that include recruitment of aberrant co-repressor complexes, alterations in chromatin remodeling, and disruption of specific subnuclear compartments. The identification and analysis of common and specific target genes regulated by AML fusion proteins will be of fundamental importance for the full understanding of acute myeloid leukemogenesis and for the implementation of disease-specific drug design.
Oncogene | 1998
Marta Fagioli; Myriam Alcalay; Lucia Tomassoni; Pier Francesco Ferrucci; Amedea Mencarelli; Daniela Riganelli; Francesco Grignani; Tullio Pozzan; Ildo Nicoletti; Fausto Grignani; Pier Giuseppe Pelicci
PML/RARα is the abnormal protein product of the Acute Promyelocytic Leukemia-specific 15;17 translocation. Both the PML and RARα components are required for the PML/RARα biological activities, namely its capacity to block differentiation and to increase survival of haematopoietic precursors. The physiological role of PML and its contribution to the function of the fusion protein are unknown. PML localizes to the cytoplasm and within specific nuclear bodies (NBs). In vitro, overexpression of PML correlates with suppression of cell transformation. The PML aminoterminal portion retained within the PML/RARα protein contains the RING finger, two newly defined cystein/histidine-rich motifs called B-boxes (B1 and B2) and a coiled-coil region. We report here that PML has a growth suppressive activity in all the cell lines tested, regardless of their transformed phenotype, and that the cellular basis for the PML growth suppression is induction of apoptotic cell death. Analysis of various nuclear and cytoplasmic PML isoforms showed that the PML growth suppressive activity correlates with its nuclear localization. Analysis of the localization and growth suppressive activity demonstrated that: (i) the Ring+B1-B2 and coiled-coil regions are both indispensable and sufficient to target PML to the NBs; (ii) individual deletions of the various PML domains have no effect on its growth suppressor activity; (iii) the Ring+B1-B2 region exerts a partial growth suppressor activity but its fusion with the coiled-coil region is sufficient to recapitulate the suppressive function of wild type PML. These results indicate that PML is involved in cell survival regulation and that the PML component of the fusion protein (Ring+B1-B2 and coiled-coil regions) retains intact biological activity, thereby suggesting that the effects of PML/RARα on survival derive from the activation of the incorporated PML sequence.
Oncogene | 1998
Martin Ruthardt; Annette Orleth; Lucia Tomassoni; Elena Puccetti; Daniela Riganelli; Myriam Alcalay; Roberta Mannucci; Ildo Nicoletti; Francesco Grignani; Marta Fagioli; Pier Giuseppe Pelicci
Acute promyelocytic leukaemia is characterized by translocations that involve the retinoic acid receptor α (RARα) locus on chromosome 17 and the PML locus on 15 or the PLZF locus on 11. The resulting abnormal translocation products encode for PML/RARα or PLZF/RARα fusion proteins. There is increasing experimental evidence that the APL-specific fusion proteins have similar biologic activities on differentiation and survival and that both components of the fusion proteins (PML or PLZF and RARα) are indispensable for these biological activities. The physiologic function of PML or PLZF or whether PML and PLZF contribute common structural or functional features to the corresponding fusion proteins is not known. We report here immunofluorescence studies on the cellular localization of PLZF and PLZF/RARα and compare it with the localization of PML and PML/RARα. PLZF localizes to nuclear domains of 0.3-0.5 microns, approximately 14 per cell in the KG1 myeloid cell line. These PLZF-bodies are morphologically similar to the domains reported for PML (PML-NBs). There is tight spatial relationship between about 30% of PLZ-NBs and PML-NBs: they partially overlap. However, PML and PLZF do not form soluble complexes in vivo. PLZF- and PML-NBs are functionally distinct. Adenovirus E4-ORF3 protein expression alters the structure of the PML-NBs and interferon increases the number of PML-NBs and neither has any effect on PLZF NBs. The localization of PLZF/RARα is different to that of PLZF and RARα. The nuclear distribution pattern of PLZF/RARα is one of hundreds of small dots (microspeckles) less than 0.1 micron. Expression of PLZF/RARα did not provoke disruption of the PML-NBs. Co-expression of PML/RARα and PLZF/RARα in U937 cells revealed apparent colocalization. Overall the results suggest that the PML- and PLZF-NBs are distinct functional nuclear domains, but that they may share common regulatory pathways and/or targeting sequences, as revealed by the common localization of their corresponding fusion proteins.
Molecular Immunology | 1994
Paolo Rovero; Daniela Riganelli; Doriana Fruci; Stefania Viganò; Stefano Pegoraro; Roberto P. Revoltella; Giulia Greco; Richard H. Butler; Sergio Clementi; Tanigaki Nobuyuki
In this paper we report a chemometric approach to Quantitative Structure-Activity Relationship (QSAR) analysis applied to a study of the binding of peptides to Major Histocompatibility Complex (MHC) class I proteins. Peptides which possess the known primary anchor residue motif for HLA-B27 binding do not necessarily bind to HLA-B27 proteins. Secondary anchor residues are also involved, but it is not yet clear which amino acids are required or in which positions. A classic approach to this problem would be to synthesize multiple peptides each varying by a single amino acid from a starting peptide, and test them for their binding properties. Not only is this approach inefficient, but it is essentially unable to provide information about possible mutual interactions of amino acid residues in different positions. Using a statistical design to select the most informative compounds to use in the QSAR study, it was possible to analyse the effects on HLA-B27 peptide binding of different amino acids in four positions by means of only nine peptides. The relative binding activity of these peptides could then be modeled mathematically to provide information about the relative contribution of each of the four positions and to suggest a new peptide with high binding affinity. Our results demonstrate the usefulness of the chemometric strategy for studying peptides of interest in molecular immunology.
Tetrahedron Computer Methodology | 1990
Sergio Clementi; Gabriele Cruciani; Daniela Riganelli; Paolo Rovero; Vittorio Pestellini; Carlo Alberto Maggi; Massimo Baroni
Abstract This paper shows the advantages of using chemometric strategies in QSAR of NKA analogues containing D-Tryptophan and behaving as highly selective NK-2 receptor antagonists: a) detecting the sequence with optimal antagonist activity, and b) having a strategy for selecting a few most informative sequences. The data set is included on disk as RVD .DAT.
Cancer Research | 1998
Francesco Grignani; Todd Kinsella; Amedea Mencarelli; Mauro Valtieri; Daniela Riganelli; Fausto Grignani; Luisa Lanfrancone; Cesare Peschle; Garry P. Nolan; Pier Giuseppe Pelicci
Quantitative Structure-activity Relationships | 1993
Massimo Baroni; Gabriele Costantino; Gabriele Cruciani; Daniela Riganelli; Roberta Valigi; Sergio Clementi
Blood | 1997
Brunangelo Falini; Leonardo Flenghi; Marta Fagioli; Francesco Lo Coco; Iole Cordone; Daniela Diverio; Laura Pasqualucci; Andrea Biondi; Daniela Riganelli; Annette Orleth; Arcangelo Liso; Massimo F. Martelli; Pier Giuseppe Pelicci; Stefano Pileri